Biography
I chose this field because half of all cancers in men – and almost 20% in women – arise in urologic organs and are treated by urologists. Specializing in urologic oncology is a way of helping many people.
Since I believe that an informed patient makes the wisest decisions regarding treatment, I spend much time educating my patients about their disease and options for treatment. My approach to patient care is individualized, both in terms of treatments offered and recommended, and in terms of the patient's and his or her family's goals. Treating bladder, kidney, prostate and testicular cancer are among my areas of expertise. I also hold several research grants and patents related to the field of urologic cancer.
Conditions I Treat:
- Bladder cancer
- Kidney cancer
- Prostate cancer
- Testicular cancer
- Adrenal cancer
- Penile cancer
- Scrotal cancer
- Ureteral cancer
- Urethral cancer
Professional Background
Dr. Messing received his MD degree from New York University in 1972, had his surgery training at NYU-Bellevue Hospital in New York 1972-1974, and his Urology Residency at Stanford University 1974-1978. After 2 years on the faculty at Tulane University, he completed a fellowship in Urologic Oncology at UCLA in 1982. He was on the faculty of the Division of Urology at the University of Wisconsin from 1982-1995, being Director of their Urologic Oncology Program for the last 10 years. He became The W.W. Scott Professor and Chairman of the Department of Urology and maintained that position until he stepped down as Chairman in January, 2018. He remains an active clinician and surgeon and is a Professor of Urology, Oncology, and Pathology at University of Rochester. At the University of Rochester School of Medicine and Dentistry(UR) in September 1995, Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the prostate, bladder, kidney, testicle, penis and other genitourinary organs, carries on extensive research in the basic biology of bladder and prostate cancers, and has been the principal investigator on numerous clinical studies for the detection, prevention and treatment of genitourinary cancers.
Dr. Messing has held numerous leadership positions in institutional, local , regional and national organizations including being a department chairman or over 22 years. interim director of the National Cancer Institute, URMC Cancer Center, being a board member, officer and president of both The Society of Urological Oncology and The North Western Section of the American Urological Association (NSAUA), co chairman of the Genitourinary Group (GU) of the Eastern Cooperative Oncology Group (ECOG) and co-leader of the Renal Cancer Subcommittee of the GU committee of SWOG. (The South West Oncology Group) In September, 2021 he will become the President-elect of the American Urological Association (AUA) to become President May, 2022.
Research
Dr. Messing is an internationally renowned expert in all facets of urologic oncology, both as a clinician/surgeon, and as a clinical, translational and basic researcher.
His research contributions have ranged from enhancing our knowledge about the basic molecular biology and genetics of development and progression of cancers of the bladder, prostate and kidney, and bringing these studies to fruition for the detection, prevention and treatment of these diseases. He has also designed and conducted landmark phase III clinical trials for each of these cancers and has carried out the first screening trial for bladder cancer in a general population. Important work has included defining the roles of epidermal growth factor (EGF) and its cell surface receptor in urothelial carcinogenesis and progression, investigating polyamine synthesis inhibition as a means to prevent bladder and prostate cancers, in large phase III clinical trials studying DFMO's ability to prevent bladder cancer's recurrence, the timing of androgen deprivation therapy (ADT) in treating regionally advanced completely resected prostate cancer, the effectiveness of adjuvant alpha interferon for completely resected, locally extensive, renal cell carcinoma, and the role of a single intravesical instillation of gemcitabine in preventing recurrence of low grade non-muscle invading bladder cancer (NMIBC). He has also contributed importantly to trials testing various forms of intravesical therapy for high risk, NMIBC, and the value of radiation therapy after prostatectomy for stage pT3 prostate cancer. He has demonstrated the feasibility of screening for bladder cancer (using hematuria reagent strips) and has worked on the development and testing of several molecular markers for the detection of bladder cancer.
Furthermore, his clinical trial work continues as the study coordinator (PI) of a large phase III clinical trial of immediate post TURBT intravesical instillation therapy for prevention of recurrence of low risk bladder cancer.Much of the above mentioned work continues, but currently he is also investigating gender disparities in bladder cancer's incidence and outcome. These efforts have ranged from investigations using large, national data bases, to molecular studies in cells and transgenic animal models. Additionally, he along with his basic science collaborators are investigating the preventative and therapeutic roles of nuclear transcription factors, vitamins and related molecules in prevention and treatment of prostate and bladder cancer.
Awards
2020
SUO Distinguished Service Award
Sponsor: Society of Urological Oncology
2018
Robert S. Davis Teaching Award
Sponsor: URMC, Department of Urology
2018
Ramon Guiteras Award
Sponsor: American Urological Association
2016
George E. Slotkin Lecturer
Sponsor: Northeast Section-AUA
2016
SUO Medal Recipient
Sponsor: Society of Urologic Oncology
2013
Presidential Citation Award
Sponsor: American Urological Association
Location: San Diego, California
2013
2013 Best of Posters Award - AUA - 2013 Annual Meeting
Sponsor: American Urological Association
Location: San Diego, California
2012
2012 Best of Posters Award – AUA – 2012 Annual Meeting
Sponsor: American Urological Association
Location: Atlanta, Georgia
2010 - Present
2010 Best of Posters Award - AUA - 2010 Annual Meeting
Sponsor: American Urological Association
Location: San Francisco, California
2009
Davey Award
Sponsor: James P. Wilmot Cancer Center
Location: University of Rochester Medical Center
2007 - Present
American Association of Genitourinary Surgeons (AAGUS)
1999 - 1999
CaP Cure Award and Best Clincal Research Prostate Cancer
Sponsor: CaP Cure
Location: Best Clinical Research on Prostate Cancer
1986 - Present
Fellow
Sponsor: American College of Surgeons
Location: American College of Surgeons
1985 - Present
Sigma Xi
Sponsor: The Scientific Research Society
1984 - 1986
Junior Faculty Clinical Fellow
Sponsor: American Cancer Society
1977 - 1977
First Prize for Clinical Research and the Bill Smart Award for Best Clinical Paper (Interstitial Cystitis)
Location: Northern California Urology Residents Seminar - Stanford, CA
1975 - 1975
Second Prize for Case Reports (Renal Arteriovenous Fistulas)
Location: Northern California Urology Residents Seminar - Davis, CA
1972 - Present
Alpha Omega Alpha
Location: New York University - School of Medicine
1972 - 1972
The Samuel Soifer Memorial Award for Outstanding Work in Urology - 1972
Location: New York University - School of Medicine
1968 - Present
Phil Beta Kappa
Location: University of Chicago
VIEW ALL expand_more
Publications
Journal Articles
1/22/2022
Kerns SL, Amidon Morlang A, Lee SM, Peterson DR, Marples B, Zhang H, Bylund K, Rosenzweig D, Hall W, De Ruyck K, Rosenstein BS, Stock RG, Gómez-Caamaño A, Vega A, Sosa-Fajardo P, Taboada-Valladares B, Aguado-Barrera ME, Parker C, Veldeman L, Fonteyne V, Bultijnck R, Talbot CJ, Paul Symonds R, Johnson K, Rattay T, Webb A, Lambrecht M, de Ruysscher D, Vanneste B, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Rancati T, Avuzzi B, Valdagni R, Azria D, Farcy Jacquet MP, Chang-Claude J, Seibold P, West C, Janelsins M, Chen Y, Messing E, Morrow G, . "Use of Angiotensin Converting Enzyme Inhibitors is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.. 2022 Jan 22; Epub 2022 Jan 22.
2022
Zhang H, Yang H, Bandyopadhyay S, Milano MT, Fung C, Messing EM, Chen Y. "Increased risk of high-grade prostate cancer among testicular cancer survivors." PloS one.. 2022 17(2):e0263573. Epub 2022 Feb 14.
5/2021
Ellis EE, Messing EM. "Active Surveillance of Small Renal Masses: A Systematic Review". Kidney Cancer. 2021; .
Books & Chapters
2015
Chapter Title: HGT1 Bladder Cancer: Diagnosis and Treatment
Book Title: Bladder Cancer: Diagnosis and Clinical Management.
Author List: Gaya JM, Palou J, Messing EM
Edited By: Lerner S, Sternberg C, Schoenberg M
Published By: Wiley-Blackwell 2015
2014
Chapter Title: Epidemiology and Natural History
Book Title: Bladder Cancer
Author List: Messing EM, Scosyrev E
Edited By: Konety B, Chang S
Published By: Springer 2014
2011
Chapter Title: Bladder Cancer: Epidemiology, risk factors, screening and chemoprevention
Book Title: Essentials and Updates in Urologic Oncology, 1st Edition
Author List: Knopf J, Trivedi D, Messing EM
Published By: Nova Science Publishers, Inc. 2011
VIEW ALL PUBLICATIONS